Table 2 Identified risk factors for allopurinol-induced MCARs
Risk factors | MCAR (n = 74) | Control (n = 395) | OR (95% CI) | P value |
|---|---|---|---|---|
Age, years, mean (SD) | ||||
 ≤ 40 | 29 (39.2) | 135 (34.2) | 1.28 (0.76–2.13) | 0.35 |
 40–65 | 42 (56.8) | 249 (63.0) | 1 |  |
 > 65 | 3 (4.0) | 11 (2.8) | 1.79 (0.44–5.67) | 0.38 |
Female, n (%) | 0 | 0 | Â | 1 |
History of allopurinol-induced skin reaction, n (%) | 2 (2.7) | 0 | 27 (2–3777) | 0.01 |
Asymptomatic hyperuricemia, n (%) | 2 (2.7) | 0 | NA | NA |
Allopurinol starting dose > 150 mg/day, n (%) | 3 (4.1) | 7 (1.8) | 2.5 (0.6–8.7) | 0.19 |
Concomitant diuretics intake, n (%) | 1 (1.4) | 0 | 16 (0.9–2365) | 0.06 |
eGFR < 60 ml/min/1.73 m2, n (%) | 6 (8.1) | 7 (1.8) | 4.9 (1.6–14.6) | 0.006 |
HLA-B*58:01-positive, n (%) | 6 (8.1) | 29 (7.3) | 1.18 (0.45–2.7) | 0.72 |